Journal
NUCLEAR MEDICINE AND BIOLOGY
Volume 29, Issue 4, Pages 431-442Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0969-8051(02)00294-9
Keywords
radioimmunotherapy; Lu-177; DOTA; PA-DOTA; CHX-A ''
Ask authors/readers for more resources
The studies reported herein present the first in vitro and in vivo comparison of radioimmunoconjugates (RIC) radiolabeled with Lu-177 using the acyclic CHX-A-DTPA ligand and the macrocyclic ligands, C-DOTA and PA-DOTA. The in vivo studies include pharmacokinetics and biodistribution of the formed Lu-177-labeled immunoconjugates in a tumor bearing murine model with engineered monoclonal antibody HuCC49DeltaCH2. The in vitro analysis indicated that the CHX-A RIC was superior with respect to immunoreactiviry, radiolabeling with Lu-177, and specific activity. The in vivo pharmacokinetic data by itself indicated that the Lu(III)-PA-DOTA complex may not be as stable as Lu(III) complexes with CHX-A or C-DOTA. All three RICs demonstrated tumor targeting of human colon carcinoma xenografts in athymic mice. In these biodistribution studies, there appears to be no overall pattern or trend of one RIC over the other two. Based on these in vitro and in vivo studies, the CHX-A DTPA ligand should be considered a suitable bifunctional chelate for the radiolabeling of monoclonal antibodies with Lu-177 for radioimmunotherapy applications. Published by Elsevier Science Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available